Markus Warmuth H3 Biomedicine Biography Publications Institution JoVE Articles Markus Warmuth has not added a biography. If you are Markus Warmuth and would like to personalize this page please email our Author Liaison for assistance. Publications Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3? Splice Site Selection Through Use of a Different Branch Point Cell Reports. Nov, 2015 | Pubmed ID: 26565915 Total Synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 Cancer Cell Line Organic Letters. Nov, 2014 | Pubmed ID: 25376106 NAMPT is the Cellular Target of STF-31-like Small-molecule Probes ACS Chemical Biology. Oct, 2014 | Pubmed ID: 25058389 Synthesis, Structure-activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials Journal of Medicinal Chemistry. Jul, 2013 | Pubmed ID: 23742252 The Cancer Cell Line Encyclopedia Enables Predictive Modelling of Anticancer Drug Sensitivity Nature. Mar, 2012 | Pubmed ID: 22460905 Trisomy 12 and Elevated GLI1 and PTCH1 Transcript Levels Are Biomarkers for Hedgehog-inhibitor Responsiveness in CLL Blood. Jan, 2012 | Pubmed ID: 22130798 Maintenance of Adenomatous Polyposis Coli (APC)-mutant Colorectal Cancer is Dependent on Wnt/beta-catenin Signaling Proceedings of the National Academy of Sciences of the United States of America. Oct, 2011 | Pubmed ID: 21949247 Genomic Sequencing of Colorectal Adenocarcinomas Identifies a Recurrent VTI1A-TCF7L2 Fusion Nature Genetics. Oct, 2011 | Pubmed ID: 21892161 Protein Kinase C Inhibitor Sotrastaurin Selectively Inhibits the Growth of CD79 Mutant Diffuse Large B-cell Lymphomas Cancer Research. Apr, 2011 | Pubmed ID: 21324920 Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist ACS Medicinal Chemistry Letters. Jun, 2010 | Pubmed ID: 24900187 Loss of the Tumor Suppressor Snf5 Leads to Aberrant Activation of the Hedgehog-Gli Pathway Nature Medicine. Dec, 2010 | Pubmed ID: 21076395 Allosteric Inhibition of BCR-ABL Cell Cycle (Georgetown, Tex.). Sep, 2010 | Pubmed ID: 20930519 Hedgehog Pathway Activation in Chronic Myeloid Leukemia Cell Cycle (Georgetown, Tex.). Sep, 2010 | Pubmed ID: 20928937 Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma Science Translational Medicine. Sep, 2010 | Pubmed ID: 20881279 The ITK-SYK Fusion Oncogene Induces a T-cell Lymphoproliferative Disease in Mice Mimicking Human Disease Cancer Research. Aug, 2010 | Pubmed ID: 20670954 A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "gatekeeper" Mutant of Bcr-Abl Journal of Medicinal Chemistry. Aug, 2010 | Pubmed ID: 20604564 The Polycomb Group Protein Bmi-1 is Essential for the Growth of Multiple Myeloma Cells Cancer Research. Jul, 2010 | Pubmed ID: 20530672 Inhibitors of the Abl Kinase Directed at Either the ATP- or Myristate-binding Site Biochimica Et Biophysica Acta. Mar, 2010 | Pubmed ID: 20152788 Targeting Bcr-Abl by Combining Allosteric with ATP-binding-site Inhibitors Nature. Jan, 2010 | Pubmed ID: 20072125 A Conserved Salt Bridge in the G Loop of Multiple Protein Kinases is Important for Catalysis and for in Vivo Lyn Function Molecular Cell. Jan, 2009 | Pubmed ID: 19150426 Measuring the Tyrosine Kinase Activity: a Review of Biochemical and Cellular Assay Technologies Expert Opinion on Drug Discovery. Aug, 2008 | Pubmed ID: 23484970 Expansion of Bcr-Abl-positive Leukemic Stem Cells is Dependent on Hedgehog Pathway Activation Cancer Cell. Sep, 2008 | Pubmed ID: 18772113 Clinical Stage EGFR Inhibitors Irreversibly Alkylate Bmx Kinase Bioorganic & Medicinal Chemistry Letters. Nov, 2008 | Pubmed ID: 18667312 Role of P21(WAF1/CIP1) As an Attenuator of Both Proliferative and Drug-induced Apoptotic Signals in BCR-ABL-transformed Hematopoietic Cells Annals of Hematology. Mar, 2008 | Pubmed ID: 17960378 Src Family Tyrosine Kinases Phosphorylate Flt3 on Juxtamembrane Tyrosines and Interfere with Receptor Maturation in a Kinase-dependent Manner Annals of Hematology. Nov, 2007 | Pubmed ID: 17668209 Essential Role of Stromally Induced Hedgehog Signaling in B-cell Malignancies Nature Medicine. Aug, 2007 | Pubmed ID: 17632527 B-Raf Kinase Inhibitors for Cancer Treatment Current Opinion in Investigational Drugs (London, England : 2000). Jun, 2007 | Pubmed ID: 17621874 Identification of NVP-TAE684, a Potent, Selective, and Efficacious Inhibitor of NPM-ALK Proceedings of the National Academy of Sciences of the United States of America. Jan, 2007 | Pubmed ID: 17185414 Ba/F3 Cells and Their Use in Kinase Drug Discovery Current Opinion in Oncology. Jan, 2007 | Pubmed ID: 17133113 Profiling the Kinome for Drug Discovery Drug Discovery Today. Technologies. 2006 | Pubmed ID: 24980528 A General Strategy for Creating "inactive-conformation" Abl Inhibitors Chemistry & Biology. Jul, 2006 | Pubmed ID: 16873026 An Efficient Rapid System for Profiling the Cellular Activities of Molecular Libraries Proceedings of the National Academy of Sciences of the United States of America. Feb, 2006 | Pubmed ID: 16492761 Requirement of Src Kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic Leukemia but Not Chronic Myeloid Leukemia Nature Genetics. May, 2004 | Pubmed ID: 15098032 SRC Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia Current Pharmaceutical Design. 2003 | Pubmed ID: 14529415 The Effects of Bcr-Abl on C/EBP Transcription-factor Regulation and Neutrophilic Differentiation Are Reversed by the Abl Kinase Inhibitor Imatinib Mesylate Blood. Jan, 2003 | Pubmed ID: 12393654 Dual-specific Src and Abl Kinase Inhibitors, PP1 and CGP76030, Inhibit Growth and Survival of Cells Expressing Imatinib Mesylate-resistant Bcr-Abl Kinases Blood. Jan, 2003 | Pubmed ID: 12393636 Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms Manav Korpal1, Jacob Feala1, Xiaoling Puyang1, Jian Zou1, Alex H. Ramos2, Jeremy Wu1, Timm Baumeister1, Lihua Yu1, Markus Warmuth1, Ping Zhu1 1H3 Biomedicine, 2Massachusetts General Hospital JoVE 52879 Medicina
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms Manav Korpal1, Jacob Feala1, Xiaoling Puyang1, Jian Zou1, Alex H. Ramos2, Jeremy Wu1, Timm Baumeister1, Lihua Yu1, Markus Warmuth1, Ping Zhu1 1H3 Biomedicine, 2Massachusetts General Hospital JoVE 52879 Medicina